Constitutive cytokine production by primary effusion (body cavity-based) lymphoma-derived cell lines

被引:58
作者
Drexler, HG
Meyer, C
Gaidano, G
Carbone, A
机构
[1] DSMZ, German Collect Microorganisms & Cell Cultures, Dept Human & Anim Cell Cultures, D-38124 Braunschweig, Germany
[2] Univ Eastern Piedmont Amedeo Avogadro, Dept Med Sci, Div Internal Med, Novara, Italy
[3] Ctr Riferimento Oncol, IRCCS, Ist Nazl Tumori, Div Pathol, I-33081 Aviano, Italy
关键词
cytokines; PEL; BCBL; cell lines;
D O I
10.1038/sj.leu.2401371
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Primary effusion lymphoma (PEL) is a new lymphoma entity occurring predominantly, but not exclusively in HIV+ patients with acquired immunodeficiency syndrome (AIDS). PEL grows exclusively in body cavities as serous lymphomatous effusion without evidence of mass disease or dissemination. The cells are infected with the newly discovered human herpesvirus-8 (HHV-8), often accompanied by co-infection with Epstein-Barr virus (EBV). Several lymphoma cell lines have been established from patients with AIDS- and non-AIDS-associated PEL. Given their phenotypical relationship to plasma cells, several cytokines may be important for growth and survival of PEL cells. We investigated the spectrum of cytokines produced by nine HHV-8+ PEL cell lines, in comparison with five Burkitt lymphoma, seven other B non-Hodgkin's lymphoma (B-NHL) and seven multiple myeloma-derived cell lines. In addition, we tested the response of the PEL cells to selected cytokines and the effects of neutralizing anti-cytokine and anti-cytokine receptor antibodies. Using specific ELISAs, PEL cell lines were found to produce large amounts of interleukin-6 (IL-6; 10-5000 pg/ml), IL-6 soluble receptor (IL-6sR; 30-600 pg/ml), IL-10 (600-80 000 pg/ml) and oncostatin M (OSM; 50-80 pg/ml) which in most cases were significantly higher than the levels produced by the Burkitt, B-NHL or myeloma cell lines; on the contrary, PEL cell lines did not elaborate significant levels of macrophage inhibitory protein (MIP-1 alpha) and leukemia inhibitory factor (LIF). However, the levels of MIP-1 alpha were increased 10- to 100-fold by treatment with phorbol ester TPA. PEL cell lines did not respond proliferatively to IL-6, IL-10, IL-11, LIF, MIP-1 alpha, or OSM. Incubation with IL-6sR and IL-6 inhibited cell growth. Anti-IL6 neutralizing antibodies had no effect on PEL cell line proliferation; conversely, whereas anti-IL6R alone inhibited only weakly, anti-gp130 and anti-gp130 plus anti-IL6R showed strong inhibitory effects (>20% inhibition in 5/9 lines and >60% inhibition in 3/9 lines). In summary, PEL cell lines produce high amounts of cytokines (IL-6, IL-10, OSM); proliferation could be inhibited by blocking the receptors of the IL-6 signaling pathway.
引用
收藏
页码:634 / 640
页数:7
相关论文
共 37 条
[1]   Mechanisms of growth control of Kaposi's sarcoma-associated herpes virus-associated primary effusion lymphoma cells [J].
Asou, H ;
Said, JW ;
Yang, R ;
Munker, R ;
Park, DJ ;
Kamada, N ;
Koeffler, HP .
BLOOD, 1998, 91 (07) :2475-2481
[2]   HUMAN-B CELL INTERLEUKIN-10 [J].
BENJAMIN, D ;
PARK, CD ;
SHARMA, V .
LEUKEMIA & LYMPHOMA, 1994, 12 (3-4) :205-210
[3]   Human herpesvirus type 8 interleukin-6 homologue is functionally active on human myeloma cells [J].
Burger, R ;
Neipel, F ;
Fleckenstein, B ;
Savino, R ;
Ciliberto, G ;
Kalden, JR ;
Gramatzki, M .
BLOOD, 1998, 91 (06) :1858-1863
[4]   Establishment and characterization of EBV-positive and EBV-negative primary effusion lymphoma cell lines harbouring human herpesvirus type-8 [J].
Carbone, A ;
Cilia, AM ;
Gloghini, A ;
Capello, D ;
Todesco, M ;
Quattrone, S ;
Volpe, R ;
Gaidano, G .
BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (04) :1081-1089
[5]  
Carbone A, 1997, INT J CANCER, V73, P562, DOI 10.1002/(SICI)1097-0215(19971114)73:4&lt
[6]  
562::AID-IJC18&gt
[7]  
3.0.CO
[8]  
2-B
[9]   HHV-8-positive body-cavity-based lymphoma: A novel lymphoma entity [J].
Carbone, A ;
Gaidano, G .
BRITISH JOURNAL OF HAEMATOLOGY, 1997, 97 (03) :515-522
[10]   KAPOSIS SARCOMA-ASSOCIATED HERPESVIRUS-LIKE DNA-SEQUENCES IN AIDS-RELATED BODY-CAVITY-BASED LYMPHOMAS [J].
CESARMAN, E ;
CHANG, Y ;
MOORE, PS ;
SAID, JW ;
KNOWLES, DM .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (18) :1186-1191